Pilot study of low- vs. high-dose Rosuvastatin in minor heart attack patients and healthy controls: assessment of skin microvascular blood flow.

INTERVENTION: 40mg Rosuvastatin (Crestor) tablet administered orally once daily in the morning for 7 days. Drug tablet return will be used to monitor adherence. CONDITION: Peripheral microvascular dysfunction in non‐ST segment elevation myocardial infarction (NSTEMI). PRIMARY OUTCOME: Change in peripheral subcutaenous microvascular reactivity as assessed by laser Doppler flowmetry. SECONDARY OUTCOME: Percent change in blood low‐density lipoprotein (LDL) levels. INCLUSION CRITERIA: Post‐menopausal women (STRAW +10 definition) and age‐matched men NSTEMI group only ‐ Evidence of NSTEMI: Electrocardiographic ST‐segment depression or prominent T‐wave inversion and/or positive biomarkers of necrosis (e.g., troponin) in the absence of ST‐segment elevation and in an appropriate clinical setting (chest discomfort or anginal equivalent)